Tsai Ming-Tsun, Yang Ruey-Bing, Ou Shuo-Ming, Tseng Wei-Cheng, Lee Kuo-Hua, Yang Chih-Yu, Chang Fu-Pang, Tarng Der-Cherng
From the Division of Nephrology, Department of Medicine (Tsai, Ou, Tseng, Lee, C-Y Yang, Tarng), Taipei Veterans General Hospital, Taipei, Taiwan.
From the Institute of Clinical Medicine, School of Medicine (Tsai, Ou, Tseng, Lee, C-Y Yang, Tarng), National Yang Ming Chiao Tung University, Taipei, Taiwan.
Arch Pathol Lab Med. 2023 Feb 1;147(2):167-176. doi: 10.5858/arpa.2021-0466-OA.
CONTEXT.—: Galectin-9 reduces tissue damage in certain immune-mediated glomerular diseases. However, its role in structural and functional renal changes in patients with varying types of chronic kidney disease (CKD) is less clear.
OBJECTIVE.—: To investigate the association between plasma galectin-9 levels, proteinuria, tubulointerstitial lesions, and renal function in different CKD stages.
DESIGN.—: We measured plasma galectin-9 levels in 243 patients undergoing renal biopsy for determining the CKD etiology. mRNA and protein expression levels of intrarenal galectin-9 were assessed by quantitative real-time polymerase chain reaction and immunostaining. Relationships between plasma galectin-9, clinical characteristics, and tubulointerstitial damage were analyzed with logistic regression. We investigated galectin-9 expression patterns in vitro in murine J774 macrophages treated with differing stimuli.
RESULTS.—: To analyze the relationship between galectin-9 and clinical features, we divided the patients into 2 groups according to median plasma galectin-9 levels. The high galectin-9 group tended to be older and to have decreased renal function, higher proteinuria, and greater interstitial fibrosis. After multivariable adjustment, elevated plasma galectin-9 levels were independently associated with stage 3b or higher CKD. An analysis of gene expression in the tubulointerstitial compartment in the biopsy samples showed a significant positive correlation between intrarenal galectin-9 mRNA expression and plasma galectin-9 levels. Immunohistochemistry confirmed increased galectin-9 expression in the renal interstitium of patients with advanced CKD, and most galectin-9-positive cells were macrophages, as determined by double-immunofluorescence staining. In vitro experiments showed that galectin-9 expression in macrophages was significantly increased after interferon-γ stimulation.
CONCLUSIONS.—: Our findings suggest that plasma galectin-9 is a good biomarker for diagnosing advanced CKD.
半乳糖凝集素-9可减轻某些免疫介导的肾小球疾病中的组织损伤。然而,其在不同类型慢性肾脏病(CKD)患者的肾脏结构和功能变化中的作用尚不清楚。
研究不同CKD阶段血浆半乳糖凝集素-9水平、蛋白尿、肾小管间质病变和肾功能之间的关联。
我们测量了243例接受肾活检以确定CKD病因的患者的血浆半乳糖凝集素-9水平。通过定量实时聚合酶链反应和免疫染色评估肾内半乳糖凝集素-9的mRNA和蛋白表达水平。采用逻辑回归分析血浆半乳糖凝集素-9、临床特征和肾小管间质损伤之间的关系。我们在体外研究了用不同刺激物处理的小鼠J774巨噬细胞中半乳糖凝集素-9的表达模式。
为分析半乳糖凝集素-9与临床特征之间的关系,我们根据血浆半乳糖凝集素-9水平中位数将患者分为两组。半乳糖凝集素-9水平高的组往往年龄较大,肾功能下降,蛋白尿更高,间质纤维化更严重。多变量调整后,血浆半乳糖凝集素-9水平升高与3b期或更高阶段的CKD独立相关。对活检样本肾小管间质区基因表达的分析显示,肾内半乳糖凝集素-9 mRNA表达与血浆半乳糖凝集素-9水平之间存在显著正相关。免疫组织化学证实晚期CKD患者肾间质中半乳糖凝集素-9表达增加,通过双重免疫荧光染色确定,大多数半乳糖凝集素-9阳性细胞为巨噬细胞。体外实验表明,干扰素-γ刺激后巨噬细胞中半乳糖凝集素-9表达显著增加。
我们的研究结果表明,血浆半乳糖凝集素-9是诊断晚期CKD的良好生物标志物。